Posted by Michael Wonder on 01 Jun 2022
Novartis announces FDA approval of Beovu for the treatment of diabetic macular oedema
1 June 2022 - Approval is based on year one data from the Phase III KESTREL and KITE clinical trials investigating Beovu (brolucizumab-dbll) 6 mg versus aflibercept 2 mg in diabetic macular oedema patients.
Novartis today announced that the US FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular oedema.
